Probatebeta
Target

CACNA1D

Voltage-dependent L-type calcium channel subunit alpha-1D

As of the edition of 20 October 2026, CACNA1D (voltage-dependent L-type calcium channel subunit alpha-1D, UniProt Q01668) has 25 drugs tested at it and 42 companies on the list, 1 on route A and 12 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q01668
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
6
Disease areas
Heart and blood vessels; Nutrition and metabolism; Nervous system; Urinary and reproductive; Pregnancy and women's health; Hormones; Mental health; Lungs and airways
Registered trials of its drugs
776

Drugs at this target

StatusCount
Marketed19
Went quiet3
Stopped1
Status not established2
Total25
DrugStatusFurthest phaseUS protection
AmlodipineMarketedPhase 4none listed
NifedipineMarketedPhase 4none listed
VerapamilMarketedPhase 4none listed
DiltiazemMarketedPhase 4none listed
ClevidipineMarketedPhase 4none listed
NicardipineMarketedPhase 4none listed
DronedaroneMarketedPhase 4none listed
NimodipineMarketedPhase 4none listed
LevamlodipineMarketedPhase 4none listed
AZD1305Went quietPhase 2none listed
LacidipineMarketedPhase 4none listed
FelodipineMarketedPhase 4none listed

12 of 25 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A1
Route B12
Engaged16
Undetermined13
Total on the list42
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
SanofiRoute B
AstraZenecaRoute B

The other 39 companies at CACNA1D

In the product

42 companies in all; 39 are not named here, and no score is.

See the 42 companies at CACNA1D, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at CACNA1D

Other targets in heart and blood vessels

Companies holding approvals at CACNA1D